Entourage Health Corp. ETRGF ENTG(FSE:4WE) released its financial results for the three months ended March 31, 2022, revealing total revenue of $15.8 million, up 17% sequentially over Q4 2021.
Q1 2022 Financial Highlights
Gross revenue of $17.4 million, and net revenue of $15.8 million less excise tax for total net revenues of $12.4 million compared to $10.6 million for the quarter ended December 31, 2021, a 17% sequential increase and 21% year-over-year improvement.
Gross profit before changes in fair value was $2.7 million for Q1 2022, representing an increase in profit of $2.5 million or 992% due to improved efficiencies and partly due to lower inventory write-downs in Q1 2022.
Gross margins of 22% in Q1 2022 compared to (-8%) for Q4 2021 and 2.4% in Q1 2021, the improvement over the prior periods a result of lower cost to produce higher grade products, sold at higher margins across expanded distribution channels.
Adjusted EBITDA improved by $1.0 million to $563,000 in Q1, 2022, compared with negative $(432,000) in Q4, 2021, also primarily driven by strategic transformation initiatives to lower costs and partly due to generating higher-margin revenue and spending lower selling, general and administrative expenses.
Loss and comprehensive loss was $8.76 million compared to $44.5 million in Q4 2021.
Cash and cash equivalents at the end of Q1 were $9.98 million
“Our first quarter results reflect our strongest operating performance to-date – mainly from fulfilling some of the largest purchase orders in our company’s history with exemplary delivery rates while consistently producing higher-grade cannabis at higher efficiencies. All of this contributed to notable increases in our adult-use and medical sales – up over 35% from last year,” stated George Scorsis, CEO and executive chair, Entourage.
“Since implementing our strategic transformation initiatives, we have achieved sequential revenue growth and cost improvements. These initiatives continue to produce tangible benefits, including 22% gross margin expansion during the quarter. With our improved liquidity position and financial flexibility thanks to our expanded credit facilities and lenders’ support, we have the resources to continue creating long-term value for all our stakeholders,” continued Scorsis.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.